3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Small Cell Lung Carcinoma
4
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Unresectable Hepatocellular Carcinoma
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcopenia
1
Recurrent Squamous Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer NSCLC
1
Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Hepatobiliary Cancers
1
Head and Neck Neoplasms
1
Deglutition Disorders
1
Interventions
tremelimumab
1
durvalumab
1
atezolizumab
1
Therapeutics
1
Immunotherapy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Unresectable Hepatocellular Carcinoma
×
durvalumab
×
Clear all
NCT06117891
2026-05-12
REFINE-IO
Bayer
Active not recruiting
300 enrolled